MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTX Stock Price Chart Interactive Chart >
MGTX Price/Volume Stats
|Current price||$7.57||52-week high||$24.89|
|Prev. close||$7.57||52-week low||$6.59|
|Day high||$7.78||Avg. volume||159,301|
|50-day MA||$8.73||Dividend yield||N/A|
|200-day MA||$14.67||Market Cap||338.46M|
MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio
MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.
Most Popular Stories View All
MGTX Latest News Stream
|Loading, please wait...|
MGTX Latest Social Stream
View Full MGTX Social Stream
Latest MGTX News From Around the Web
Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.
-MeiraGTx Receives $30 Million Cash Milestone Payment -MeiraGTx, in Collaboration with Janssen Pharmaceuticals, Inc., is Now Dosing Patients in the Phase 3 Lumeos Clinical Trial in X-linked Retinitis Pigmentosa -MeiraGTx Remains Eligible for Further Development and Commercial Milestones Related to botaretigene sparoparvovec (AAV-RPGR), as well as for AAV-CNGB3 and AAV-CNGA3 LONDON and NEW YORK, Jan. 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinic
Recent 5.8% pullback isn't enough to hurt long-term MeiraGTx Holdings (NASDAQ:MGTX) shareholders, they're still up 106% over 3 years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of 
After Evercore ISI and Piper Sandler gave Meiragtx Holdings (NASDAQ: MGTX) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Geulah Livshits reiterated a Buy rating on Meiragtx Holdings today and set a price target of $55.00. The company's shares closed last Thursday at $19.90. According to TipRanks.com, Livshits is a top 100 analyst with an average return of 51.7% and a 51.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics, and Crispr Therapeutics AG.
MeiraGTx says it has a triggering drug that can be used to turn implanted genes on and off in people. The technology could lessen the cost of treatment for many illnesses.
MGTX Price Returns